723. Apafant

Nomenclature

CAS number: 105219-56-5
3-[4-(2-Chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-2-yl]-1-(4-morpholinyl)-1-propanone; 4-[3-[4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-2-yl]-1-oxopropyl]morpholine; WEB-2086.
C22H22ClN5O2S; mol wt 455.96.
C 57.95%, H 4.86%, Cl 7.78%, N 15.36%, O 7.02%, S 7.03%.

Description and references

Platelet activating factor (PAF) antagonist. Prepn: K. H. Weber et al, DE 3502392; eidem, US 5082839 (1986, 1992 both to Boehringer, Ing.). Pharmacology: J. Casals-Stenzel et al., J. Pharmacol. Exp. Ther. 241, 974 (1987). Clinical pharmacology, pharmacokinetics: H. M. Brecht et al., Arzneim.-Forsch. 41, 51 (1991). Clinical effect vs PAF-induced bronchoconstriction: W. S. Adamus et al., Clin. Pharmacol. Ther. 47, 456 (1990).

Chemical structure

Properties

Viscous, almost colorless oil. LD50 in mice (mg/kg): 540 i.v.; 4600 orally (Casals-Stenzel).

Use

Tool to evaluate the role of PAF in exptl models of human disease.